Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Detail)

v3.7.0.1
Commitments and Contingencies - Additional Information (Detail)
3 Months Ended 12 Months Ended
Mar. 31, 2017
USD ($)
Milestone
Dec. 31, 2017
USD ($)
Dec. 31, 2013
shares
UFRF License Agreement [Member]      
Commitment And Contingencies [Line Items]      
Company's obligation to pay from percentage of selling price of product 5.00%    
Company's obligation to pay from all revenue received from sublicenses 22.00%    
One-time commercialization fee monthly amount for calculation $ 5,000    
Post-commercialization minimum royalty payments 50,000    
One-time additional royalty payment would be due when total cumulative royalties paid to UFRF exceed amount $ 2,000,000    
One-time additional payment to UFRF as a percentage of total royalties due to UFRF 10.00%    
Minimum annual maintenance payment on license agreement $ 10,000    
Quarterly maintenance payment to UFRF under installment plan $ 2,500    
Termination notice period 90 days    
Texas A and M University License [Member]      
Commitment And Contingencies [Line Items]      
Company's obligation to pay from percentage of selling price of product 5.00%    
Post-commercialization minimum royalty payments $ 100,000    
Initial payment to Texas A&M 5,000    
Minimum consideration for the continuation of the license agreement $ 15,000    
Number of milestones achieved | Milestone 0    
Texas A and M University License [Member] | Phase 1 Clinical Trial [Member]      
Commitment And Contingencies [Line Items]      
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2019    
Milestone payment under licensing agreement $ 50,000    
Texas A and M University License [Member] | Phase 2 Clinical Trial [Member]      
Commitment And Contingencies [Line Items]      
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2022    
Milestone payment under licensing agreement $ 100,000    
Texas A and M University License [Member] | Phase 3 Clinical Trial [Member]      
Commitment And Contingencies [Line Items]      
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2025    
Milestone payment under licensing agreement $ 150,000    
Texas A and M University License [Member] | Sale Of Licensed Technology [Member]      
Commitment And Contingencies [Line Items]      
Date of milestone achievement under licensing agreement with Texas A&M Jun. 01, 2026    
Milestone payment under licensing agreement $ 400,000    
Texas A and M University License [Member] | Minimum [Member]      
Commitment And Contingencies [Line Items]      
Company's obligation to pay from percentage of selling price of product 2.00%    
Texas A and M University License [Member] | Scenario, Forecast [Member] | Amendment [Member]      
Commitment And Contingencies [Line Items]      
Minimum consideration for the continuation of the license agreement   $ 25,000  
Lantibiotic ECC [Member]      
Commitment And Contingencies [Line Items]      
Company's obligation to pay from percentage of selling price of product 25.00%    
Company's obligation to pay from all revenue received from sublicenses 50.00%    
Number of milestones achieved | Milestone 0    
Number of shares issued | shares     4,392,425
Maximum percentage of primary investment securities to investment of shares issued 10.00%    
Lantibiotic ECC [Member] | Investigational New Drug Application [Member]      
Commitment And Contingencies [Line Items]      
Percentage of number of shares of common stock equal to Base Shares 1.00%    
Lantibiotic ECC [Member] | Phase 2 Clinical Trial [Member]      
Commitment And Contingencies [Line Items]      
Percentage of number of shares of common stock equal to Base Shares 1.50%    
Lantibiotic ECC [Member] | New Drug Application or Biologics License Application [Member]      
Commitment And Contingencies [Line Items]      
Percentage of number of shares of common stock equal to Base Shares 2.50%    
Lantibiotic ECC [Member] | First Regulatory Approval of Oragenics Product [Member]      
Commitment And Contingencies [Line Items]      
Percentage of number of shares of common stock equal to Base Shares 3.00%    
Lantibiotic ECC [Member] | Phase 3 Clinical Trial [Member]      
Commitment And Contingencies [Line Items]      
Percentage of number of shares of common stock equal to Base Shares 2.00%    
Oral Mucositis ECC [Member]      
Commitment And Contingencies [Line Items]      
Company's obligation to pay from percentage of selling price of product 12.00%    
Company's obligation to pay from all revenue received from sublicenses 50.00%    
Number of milestones achieved | Milestone 0    
Oral Mucositis ECC [Member] | Phase 2 Milestone Event [Member]      
Commitment And Contingencies [Line Items]      
Milestone payment under licensing agreement $ 2,000,000    
Milestone measurement period 30 days    
Oral Mucositis ECC [Member] | Phase 2b/3 Milestone Event [Member]      
Commitment And Contingencies [Line Items]      
Milestone payment under licensing agreement $ 5,000,000    
Milestone measurement period 30 days    
Oral Mucositis ECC [Member] | Regulatory Approval Application Milestone Event [Member]      
Commitment And Contingencies [Line Items]      
Milestone payment under licensing agreement $ 5,000,000    
Milestone measurement period 30 days    
Oral Mucositis ECC [Member] | Approval Milestone Event [Member]      
Commitment And Contingencies [Line Items]      
Milestone payment under licensing agreement $ 10,000,000    
Milestone measurement period 30 days    
Oral Mucositis ECC [Member] | New Indication Milestone Event [Member]      
Commitment And Contingencies [Line Items]      
Milestone payment under licensing agreement $ 5,000,000    
Milestone measurement period 30 days    
Oral Mucositis ECC [Member] | New Product Milestone Event [Member]      
Commitment And Contingencies [Line Items]      
Milestone payment under licensing agreement $ 5,000,000    
Milestone measurement period 30 days    
Oral Mucositis ECC [Member] | Maximum [Member]      
Commitment And Contingencies [Line Items]      
Maturity of interest bearing promissory note 12 months